```html

Drug‑Induced Liver Injury (DILI)

Overview

Drug‑induced liver injury (DILI) is liver damage that occurs as an unintended side‑effect of prescription medications, over‑the‑counter (OTC) drugs, herbal supplements, or illicit substances. The liver is the body’s primary detoxification organ, so it is particularly vulnerable to toxic metabolites produced when drugs are broken down.

• Prevalence: DILI accounts for about 10‑15% of acute hepatitis cases and is the most common reason for a medication to be withdrawn from the market.
• Who it affects: It can occur in anyone, but certain groups—older adults, people with pre‑existing liver disease, and those taking multiple hepatotoxic drugs—are at higher risk.
• Types: DILI is classified as intrinsic (predictable, dose‑dependent, e.g., acetaminophen overdose) or idiosyncratic (unpredictable, not clearly dose‑related, often immune‑mediated).

Symptoms

Symptoms may appear within days to several months after starting a medication. They range from mild, nonspecific complaints to severe liver failure.

• Fatigue & weakness – often the first sign.
• Right‑upper‑quadrant abdominal pain – a dull ache near the liver.
• Dark urine – due to bilirubin excretion.
• Jaundice – yellowing of the skin and eyes.
• Pruritus (itching) – from bile salt accumulation.
• Nausea & vomiting – especially with high‑dose acetaminophen.
• Loss of appetite and unintended weight loss.
• Clay‑colored stools – reduced bile flow.
• Fever – may indicate a hypersensitivity reaction.
• Encephalopathy (confusion, drowsiness) – a sign of severe hepatic failure.

Causes and Risk Factors

Common Culprit Medications

• Acetaminophen (especially >4 g/day or acute overdose)
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – ibuprofen, diclofenac
• Antibiotics – amoxicillin‑clavulanate, isoniazid, nitrofurantoin
• Antifungals – fluconazole, ketoconazole
• Antiepileptics – phenytoin, carbamazepine, valproic acid
• Statins (rarely, but reported)
• Herbal and dietary supplements – kava, green tea extract, you‑gonna‑need‑a‑list

Risk Factors

• Age > 65 years – reduced liver regenerative capacity.
• Female sex – immune‑mediated idiosyncratic DILI is slightly more common in women.
• Pre‑existing liver disease (viral hepatitis, NAFLD, alcoholic liver disease).
• Genetic polymorphisms affecting drug‑metabolizing enzymes (e.g., CYP2E1, HLA‑B*57:01).
• Polypharmacy – drug–drug interactions can increase toxic metabolite formation.
• Alcohol consumption – synergistic toxicity, especially with acetaminophen.
• Obesity & metabolic syndrome – predispose to non‑alcoholic fatty liver disease, lowering the liver’s reserve.

Diagnosis

Diagnosing DILI is largely one of exclusion; clinicians must rule out viral hepatitis, autoimmune hepatitis, gallstone disease, and other causes of liver injury.

Key Steps

1. Detailed medication history – include prescription, OTC, supplements, and timing relative to symptom onset.
2. Physical examination – look for jaundice, hepatomegaly, ascites, or signs of chronic liver disease.
3. Laboratory tests
   • Serum aminotransferases (ALT, AST) – usually >5 ×  ULN in DILI.
   • Alkaline phosphatase (ALP) – ↑ in cholestatic patterns.
   • Total bilirubin.
   • International normalized ratio (INR) – assesses synthetic function.
   • Complete blood count, renal function, and serum electrolytes.
4. Imaging – abdominal ultrasound or CT to exclude obstructive disease.
5. Liver‑specific scoring systems – e.g., RUCAM (Roussel Uclaf Causality Assessment Method) helps estimate likelihood that a drug caused the injury.
6. Liver biopsy – rarely needed, but can differentiate DILI from autoimmune hepatitis or other pathologies when the diagnosis remains uncertain.

Treatment Options

Immediate Measures

• Discontinue the offending agent – the most critical step.
• If acetaminophen toxicity is suspected, administer N‑acetylcysteine (NAC) within 8 hours of overdose (per Mayo Clinic guidelines).

Supportive Care

• Intravenous fluids to maintain perfusion.
• Correction of coagulopathy with vitamin K or plasma if INR > 1.5 and bleeding risk is present.
• Monitoring for hepatic encephalopathy – lactulose may be used if encephalopathy develops.

Pharmacologic Interventions

• **Corticosteroids** – occasionally used in severe immune‑mediated DILI (e.g., drug‑induced autoimmune hepatitis).
• **Ursodeoxycholic acid** – may improve cholestatic DILI, though evidence is limited.

Definitive Therapies

• Liver transplantation – reserved for acute liver failure with a poor prognosis (MELD score ≥ 30, INR > 2, or encephalopathy). Survival rates exceed 70% per United Network for Organ Sharing (UNOS) data.

Lifestyle Measures

• Abstain from alcohol.
• Adopt a balanced diet low in saturated fats and refined sugars.
• Stay hydrated and avoid additional hepatotoxic substances.

Living with Drug‑Induced Liver Injury

While many cases resolve after drug withdrawal, some patients develop chronic liver changes. The following strategies help maintain liver health:

• Regular follow‑up labs – ALT, AST, ALP, bilirubin, and INR every 1‑3 months initially, then spacing out as values stabilize.
• Medication reconciliation – keep an up‑to‑date list of all agents; share it with every healthcare provider.
• Vaccinations – hepatitis A and B vaccines are recommended for patients with chronic liver injury.
• Exercise – at least 150 minutes of moderate aerobic activity per week improves hepatic blood flow and reduces fatty infiltration.
• Nutrition – emphasize fruits, vegetables, whole grains, and lean protein. Limit salt to <8 g/day to reduce fluid retention.
• Limit hepatotoxic exposures – avoid herbal supplements unless vetted by a clinician.
• Psychological support – chronic illness can cause anxiety; counseling or support groups can be beneficial.

Prevention

1. Prescribe the lowest effective dose and limit duration of known hepatotoxins.
2. Screen before starting therapy – baseline liver enzymes are recommended for high‑risk drugs (e.g., isoniazid, methotrexate).
3. Educate patients about warning signs and the importance of adhering to dosing instructions.
4. Use drug interaction checkers when multiple agents are needed.
5. Avoid unnecessary OTC analgesics – especially acetaminophen >2 g/day without medical supervision.
6. Monitor alcohol intake – provide counseling on safe limits.
7. Consider pharmacogenetic testing in patients with a history of DILI or known risk alleles (e.g., HLA‑B*57:01 for flucloxacillin).

Complications

If DILI is not recognized early or the offending drug is not stopped, serious complications can develop:

• Acute liver failure (ALF) – rapid loss of synthetic function, encephalopathy, and coagulopathy.
• Chronic liver disease – persistent fibrosis or cirrhosis in up to 10‑20% of severe cases.
• Portal hypertension – leading to variceal bleeding.
• Hepatocellular carcinoma – long‑term risk when cirrhosis develops.
• Systemic immune reactions – rash, eosinophilia, or renal involvement (e.g., drug‑induced hypersensitivity syndrome).

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, NIH LiverTox Database, WHO, Cleveland Clinic, American College of Gastroenterology, peer‑reviewed journals (Hepatology, J Clin Pharmacol).

```